Cash Cash Equivalents - Editas Medicine Inc (NASDAQ:EDIT) - Alpha Spread

First Time Loading...

Watchlist Manager

Watchlist

Price: 6 USD 5.63%

Updated:

Editas Medicine Inc
Cash & Cash Equivalents

Last Value

3-Years 3-Y CAGR

5-Years 5-Y CAGR

10-Years 10-Y CAGR

Quarterly

Annual

|

Adjust for Inflation

Editas Medicine Inc
Cash & Cash Equivalents Peer Comparison

ABBV

GILD

AMGN

VRTX

REGN

Company		Cash & Cash Equivalents	CAGR 3Y	CAGR 5Y	CAGR 10Y
	Editas Medicine Inc NASDAQ:EDIT	Cash & Cash Equivalents $69.2m	CAGR 3-Years -42%	CAGR 5-Years -15%	CAGR 10-Years N/A
	Abbvie Inc NYSE:ABBV	Cash & Cash Equivalents $12.8B	CAGR 3-Years 15%	CAGR 5-Years 12%	CAGR 10-Years 3%
	Gilead Sciences Inc NASDAQ:GILD	Cash & Cash Equivalents $4.7B	CAGR 3-Years 5%	CAGR 5-Years -23%	CAGR 10-Years -3%
	Amgen Inc NASDAQ:AMGN	Cash & Cash Equivalents $9.7B	CAGR 3-Years 17%	CAGR 5-Years 6%	CAGR 10-Years 10%
	Vertex Pharmaceuticals Inc NASDAQ:VRTX	Cash & Cash Equivalents $11.2B	CAGR 3-Years 23%	CAGR 5-Years 33%	CAGR 10-Years 35%
	Regeneron Pharmaceuticals Inc NASDAQ:REGN	Cash & Cash Equivalents $2.6B	CAGR 3-Years 22%	CAGR 5-Years 9%	CAGR 10-Years 19%

See Also

Based on the financial report for Mar 31, 2024, Editas Medicine Inc's Cash & Cash Equivalents amounts to 69.2m USD.

Over the last year, the Cash & Cash Equivalents growth was -46%. The average annual Cash & Cash Equivalents growth rates for Editas Medicine Inc have been -42% over the past three years , -15% over the past five years .

Join more than 137,700+ value investors using Alpha Spread

Create a free account

or see our plans & pricing

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

What is Intrinsic Value? Help Center Contact Us

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.